International partnership brings cannabinoid therapy with clinical evidence for dysmenorrhea to Brazil

HempStreet Medicare Pvt. Ltd., a company with global operations in clinically validated cannabinoid therapies, announced the launch of Formulation Femme™ in Brazil, in partnership with Entourage Phytolab.

The move brings the Indian company into one of the fastest-growing regulated medical cannabis markets in the world and expands the portfolio of solutions available in the country with a low-dose, non-psychotropic formulation aimed at women’s health.

Primary dysmenorrhea affects between 50% and 90% of women of reproductive age and is among the leading causes of school and work absenteeism among women — traditionally managed with nonsteroidal anti-inflammatory drugs (NSAIDs) or hormonal therapies.

In Brazil, Formulation Femme will be made available by Entourage Phytolab, in compliance with Anvisa’s current regulatory framework for imported cannabinoid products (RDC 660).

New therapeutic front and market positioning

The product represents a distinct scientific philosophy — grounded in integrated phytotherapeutic and cannabinoid science and designed to support the body’s natural pathways, rather than simply suppress symptoms.

The formulation is based on the growing recognition that combining plant-based active compounds — acting simultaneously on multiple biological pathways — may provide efficacy gains and reduce adverse effects compared with synthetic medicines or isolated molecules, especially in multifactorial clinical conditions.

This direction follows a broader evolution in medicine, with growing interest in systemic approaches and multi-compound formulations capable of addressing complex physiological conditions.

Technology and standardization as a competitive advantage

More recently, HempStreet has begun incorporating advanced nanoemulsion technology into its formulations, enabling a faster onset of action and more consistent absorption.

The strategy seeks to apply pharmaceutical-industry levels of reliability to botanical medicine — increasing bioavailability, reducing variability and improving the patient experience.

According to the company’s leadership, HempStreet is among the first Indian companies to adopt nanoemulsion-based cannabinoid delivery systems in clinically grounded formulations for global markets, representing a relevant advance in the integration of traditional phytotherapeutic medicine and modern drug-delivery science.

Data, artificial intelligence and formulation development

The company says it believes the next generation of phytotherapeutic and cannabinoid medicines will be driven not only by traditional knowledge and clinical research, but also by advances in artificial intelligence and advanced computational modeling, including quantum chemistry simulations for formulation stability and bioavailability.

These technologies increasingly allow researchers to simulate molecular interactions, predict safety profiles and optimize formulations before large-scale clinical validation.

When combined with real-world clinical evidence, these tools may enable the development of more precise, safe and effective phytotherapeutic and cannabinoid combinations.

“Historically, many phytotherapeutic medicines were limited by the constraints of traditional pharmaceutical discovery models,” said Abhishek Mohan, Founder and CEO of HempStreet.

“With advances in computational biology, artificial intelligence and quantum chemistry simulations, we now have the opportunity to understand complex phytotherapeutics at the molecular level. This opens the way for the responsible development of formulations with phytotherapeutic combinations that may offer superior safety and efficacy compared with conventional approaches based on isolated molecules.”

Therapeutic strategy and clinical evidence

The approach to cannabinoid medicine has prioritized low-dose formulations without psychotropic effects, with an emphasis on patient safety and responsible clinical use.

In this context, Formulation Femme is positioned among the alternatives under development for the management of dysmenorrhea. The proposal combines low-concentration cannabinoids with Ayurvedic-derived phytotherapeutics in a multi-compound formulation aligned with the concept of the entourage effect (entourage effect), which considers the joint action of different active compounds.

The strategy reflects a clinical research trend focused on integrated approaches, especially in multifactorial conditions such as menstrual pain, which is still widely treated with conventional therapies.

Partnership as an entry vector into Brazil

HempStreet’s entry into Brazil is taking place through a partnership with Entourage Phytolab, a company already active in the national medical cannabis market and operating within Anvisa’s regulatory guidelines.

The collaboration involves the distribution of Formulation Femme in the country, as well as initiatives related to medical guidance and patient access through regulated channels.

Under the agreement, Entourage Phytolab assumes exclusivity for the commercialization of the product in Brazil and gains preference in any future stages of local development and registration, subject to clinical and regulatory progress.

“Dysmenorrhea affects millions of Brazilian women and remains one of the most neglected conditions in conventional medicine. Bringing to Brazil a clinically studied, low-dose and non-psychotropic formulation is consistent with our mission: to offer Brazilian physicians and patients a serious alternative, based on evidence and within the national regulatory framework,” says Caio Abreu, CEO of Entourage Phytolab.

The collaboration aims to ensure that Brazilian patients and physicians can access clinically grounded cannabinoid therapies through regulated channels.

The Brazilian medical cannabis market continues on a path of accelerated expansion and is already approaching the mark of 1 million patients undergoing treatment in the country, according to Kaya Mind. This progress mainly reflects broader access through regulated pathways and increased medical confidence in the therapeutic use of cannabinoids.

Another indicator of this growth is the evolution of the base of qualified professionals: Brazil has already surpassed the mark of 61,000 prescribers, according to Close-UP International, including physicians and other authorized professionals, signaling greater prescription reach across different specialties and regions.

This movement is occurring alongside the maturation of the regulatory environment and the growing supply of available products, especially through the rules established by Anvisa for the importation and commercialization of cannabis-based products. Events such as the Cannabis Fair and the Brazilian Medical Cannabis Congress also highlight this growth by bringing together healthcare professionals, companies and specialists to discuss access, regulation and clinical advances in the country. Among the confirmed names, Caio Abreu, CEO of Entourage Phytolab, will speak in the business module, strengthening the debate on market strategies and the evolution of the sector in Brazil. In 2025, the two main cannabis events in Latin America brought together more than 4,600 visitors and 950 congress attendees, reinforcing their role as one of the main meeting points for the medical cannabis ecosystem in Brazil. Register

In practice, the numbers indicate a transition of the Brazilian market from an initial phase, still marked by access barriers and lack of awareness, to a more consolidated stage, with sustained growth on both the demand and medical-prescription sides.

The trend is that, with continued medical education, advances in clinical evidence and the entry of new therapeutic solutions, the country will further expand the number of patients served in the coming years, reinforcing its role as one of the world’s leading emerging medical cannabis markets.